LEVONOREGESTREL INTRAUTERINE DELIVERY SYSTEM (Mirena 52mg®)
Clinical Indication
Intra-uterine progestogen-only contraception
Comments
For use in patients with risk factors for hyperplasia, and in patients with raised BMI.
Can be used for protection from endometrial hyperplasia during oestrogen HRT.
It is advisable to use the Mirena device in women approaching menopause who also require contraception, device can be retained until after menopause has been confirmed.
Date of classification
September 2025
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.